Acasti Pharma FY2024 net loss $12.9M; STRIVE-ON trial on track for NDA in H1 2025

Grace Therapeutics, Inc.

FY2024 net loss $12.9M ($1.35 per share), down from $42.4M in FY2023; decrease due to prior year impairments not recurring and restructuring.
R&D expenses fell to $4.7M from $10.0M; G&A expenses down to $6.4M from $7.6M reflecting strategic realignment toward GTX-104.
Cash and equivalents $23.0M as of March 31, 2024; projected runway into Q2 2026.
STRIVE-ON Phase 3 safety trial enrollment on track; potential NDA submission to FDA in first half of 2025.
Completed $7.5M private placement in September 2023; deprioritized GTX-102 and GTX-101 to focus on GTX-104.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.